© 2021 MJH Life Sciences and OncLive. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
An overview of neuroendocrine tumors and comprehensive insight on the novel targeted therapies that are improving outcomes for patients.
August 20th 2021
Diane Reidy-Lagunes, MD, provides an overview of neuroendocrine tumors, along with specific considerations for optimal diagnosis and prognostication.
Expert insight on the pathogenesis of neuroendocrine tumors and the best use of molecular testing to inform treatment decisions.
August 27th 2021
Standard treatment pathways for patients with neuroendocrine tumors involving systemic therapy, surgery, and radiation.
A detailed explanation on how disease and patient factors inform selection from the treatment armamentarium for neuroendocrine tumors.
September 3rd 2021
Diane Reidy-Lagunes, MD, outlines goals of therapy and selection of systemic therapy for patients with neuroendocrine tumors.
Expert reflections on VEGF-targeted therapy’s role in the treatment of patients with neuroendocrine tumors.
September 10th 2021
Considerations for use of surufatinib in patients with neuroendocrine tumors in light of the SANET-p and SANET-ep clinical trials.
Looking toward the future management of neuroendocrine tumors, Diane Reidy-Lagunes, MD, shares insight on possible therapy evolutions and ongoing unmet needs.
September 17th 2021
Expert insight on the subtypes of neuroendocrine tumors and current understanding of the disease microenvironment.
Matthew H. Kulke, MD, provides a broad overview of initial therapy options available for patients with neuroendocrine tumors.